Waisman Biomanufacturing partners with GigaGen to manufacture new COVID-19 drug

Waisman Biomanufacturing at the University of Wisconsin–Madison will begin manufacturing a new drug to treat and prevent COVID-19, developed by California-based biotech company GigaGen. The drug, called GIGA-2050, uses a new approach similar to treating COVID-19 patients with convalescent plasma, or blood products from people recovering (convalescing) from an infection. Waisman Biomanufacturing was created to facilitate just this sort of development and testing of new types of drugs.

Inside Waisman: Meet Lindsay McCary

As a third year graduate student in school psychology at the University of South Carolina, Lindsay McCary, PhD, was looking for a new advisor to help her with her dissertation. At the time, Jane Roberts, PhD, had just joined the Department of Psychology and had some data available on younger children with the genetic disorder fragile X syndrome (FXS). McCary was immediately fascinated by the new professor’s research because it integrated both behavioral and physiological data to examine an individual’s observable characteristics.

UW–Madison’s EdNeuroLab tackling math learning through brain imaging

In 2012, Edward Hubbard, a cognitive neuroscientist and assistant professor with UW‒Madison’s Department of Educational Psychology, created the Educational Neuroscience Lab to understand — through functional magnetic resonance imaging (fMRI) — how the physical changes that occur in children’s brains as they learn may help improve education practices.

Improved technique illuminates fragile X protein

Researchers at the Waisman Center made a significant step in understanding the function of a specific protein, FMR1, whose absence causes fragile X syndrome, or FXS. Waisman investigators Xinyu Zhao, PhD, and Anita Bhattacharyya, PhD, with research associate Meng Li, published their paper “Identification of FMR1-regulated molecular networks in human neurodevelopment” in the March issue of the journal Genome Research.